In this article, we will discuss Golimumab and Injection Site Reactions. So, let’s get started.
Golimumab and Injection Site Reactions
In controlled Phase 3 trials through Week 16 in RA, PsA and AS, 6% of Golimumab-treated
patients had injection site reactions compared with 2% of control-treated patients. The majority of the injection site reactions were mild and the most frequent manifestation was injection site erythema. In controlled Phase 2 and 3 trials in RA, PsA, and AS, no patients treated with Golimumab developed anaphylactic reactions.